BEAT-PKD (NCT07282821) moved to recruiting status in September 2026. The Phase 2, randomized, double-blind, placebo-controlled trial will give 120 adults with ADPKD either bempedoic acid 180mg once daily or a matching placebo for two years. The study is led by Kenneth Hallows at the University of Vermont and funded by the U.S. Department of Defense.
Three sites are listed: the University of Vermont Medical Center (Burlington), the University of Maryland (Baltimore) and Tufts Medical Center (Boston). Participants must be 18–60 with rapidly progressive disease (Mayo Imaging Class 1C–1E, or 1B with documented eGFR decline of more than 3 mL/min/1.73m² per year) and an eGFR of at least 35. People already on a stable dose of tolvaptan can join, which matters because the trial is testing a pathway that could complement tolvaptan rather than replace it. People with diabetes, significant proteinuria or a history of gout are excluded.
Bempedoic acid is a pro-drug activated mainly in the liver and kidney. It inhibits ATP-citrate lyase and activates AMPK, the cellular energy sensor that is suppressed in ADPKD cyst cells. AMPK activation dampens both cyst-cell growth and cyst fluid secretion.
The primary endpoints are safety and tolerability. Kidney function (eGFR), MRI kidney volume and ADPKD-specific quality-of-life scores are secondary endpoints that will give the first efficacy signal. Primary completion is estimated for September 2029. Because the drug is already approved, a positive result would have an unusually short path to patients.